Abstract
Accumulation of glutaric acid (GA) and 3-hydroxyglutaric acid (3HGA) in body fluids is the biochemical hallmark of type 1 glutaric aciduria (GA1), a disorder characterized by acute striatal degeneration and a subsequent dystonia. To date, methods for quantification of 3HGA are mainly based on stable isotope dilution gas chromatography mass spectrometry (GC-MS) and require extensive sample preparation. Here we describe a simple liquid chromatography tandem MS (LC-MS/MS) method to quantify this important metabolite in dried urine spots (DUS). This method is based on derivatization with 4-[2-(N,N-dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazole (DAABD-AE). Derivatization was adopted to improve the chromatographic and mass spectrometric properties of the studied analytes. Derivatization was performed directly on a 3.2-mm disc of DUS as a sample without extraction. Sample mixture was heated at 60°C for 45 min, and 5 μl of the reaction solution was analyzed by LC-MS/MS. Reference ranges obtained were in excellent agreement with the literature. The method was applied retrospectively for the analysis of DUS samples from established low- and high-excreter GA1 patients as well as controls (n = 100). Comparison of results obtained versus those obtained by GC-MS was satisfactory (n = 14). In populations with a high risk of GA1, this approach will be useful as a primary screening method for high- or low-excreter variants. In these populations, however, DUS analysis should not be implemented before completing a parallel comparative study with the standard screening method (i.e., molecular testing). In addition, follow-up DUS GA and 3HGA testing of babies with elevated dried blood spot C5DC acylcarnitines will be useful as a first-tier diagnostic test, thus reducing the number of cases requiring enzymatic and molecular analyses to establish or refute the diagnosis of GA1.
Similar content being viewed by others
References
Al-Dirbashi OY, Jacob M, Al-Amoudi M, Al-Kahtani K, Al-Odaib A, El-Badaoui F, Rashed MS (2005) Quantification of glutaric and 3-hydroxyglutaric acids in urine of glutaric acidemia type I patients by HPLC with intramolecular excimer-forming fluorescence derivatization. Clin Chim Acta 359:179–188
Al-Dirbashi OY, Santa T, Al-Qahtani K, Al-Amoudi M, Rashed MS (2007) Analysis of organic acid markers relevant to inherited metabolic diseases by UPLC-MS/MS as benzofurazan derivatives. Rapid Commun Mass Spectrom 21:1984–1990
Al-Dirbashi OY, Santa T, Rashed MS, Al-Hassnan Z, Shimozawa N, Chedrawi A, Jacob M, Al-Mokhadab M (2008) Rapid UPLC-MS/MS method for routine analysis of plasma pristanic, phytanic, and very long chain fatty acid markers of peroxisomal disorders. J Lipid Res 49:1855–1862
Baric I, Wagner L, Feyh P, Liesert M, Buckel W, Hoffmann GF (1999) Sensitivity and specificity of free and total glutaric acid and 3-hydroxyglutaric acid measurements by stable isotope dilution assays for the diagnosis of glutaric acidurias type I. J Inher Metab Dis 22:867–882
Christensen E, Ribes A, Merinero B, Zschocke J (2004) Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 27:861–868
Funk CBR, Prasad AN, Frosk P, Sauer S, Kölker S, Greenberg CR, del Bigio M (2005) Neuropathological, biochemical, and molecular findings in a glutaric acidemia type 1 cohort. Brain 128:711–722
Gallagher RC, Cowan TM, Goodman SI, Enns GM (2005) Glutaryl-CoA dehydrogenase deficiency and newborn screening: retrospective analysis of a low excretor provides further evidence that some cases may be missed. Mol Genet Metab 86:417–420
Goodman SI, Markey SP, Moe PG, Miles BS, Teng CC (1975) Glutaric acidurias; a “new” disorder of amino acid metabolism. Biochem Med 12:12–21
Goodman SI, Frerman FE (2001) Organic acidemias due to defects in lysine oxidation: 2-ketoadipic acidemia and glutaric acidemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 2195–2204
Greenberg CR, Reimer D, Singal R, Triggs-Raine B, Chudley AE, Dilling LA, Philipps S, Haworth JC, Seargeant LE, Goodman SI (1995) A G-to-T transversion at the +5 position of intron one in the glutaryl CoA dehydrogenase gene is associated with the Island Lake variant of glutaric acidemia type I. Hum Mol Genet 4:493–495
Greenberg CR, Prasad AN, Dilling LA, Thompson JR, Haworth JC, Martin B, Wood-Steinman P, Seargeant LE, Seifert B, Booth FA, Prasad C (2002) Outcome of the first 3-years of a DNA-based neonatal screening program for glutaric academia type 1 in Manitoba and northwestern Ontario, Canada. Mol Gen Metab 75:70–78
Harting I, Neumaier-Probst E, Seitz A, Maier EM, Assmann B, Baric I, Troncoso M, Mühlhausen C, Zschocke J, Boy NPS, Hoffmann GF, Garbade SF, Kölker S (2009) Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain 132:1764–1782
Hedlund GL, Longo N, Pasquali M (2006) Glutaric Acidemia Type 1. Am J Med Genet C Semin Med Genet 142:86–94
Hoffmann GF (2006) Cerebral organic acid disorders and other disorders of lysine catabolism. In: Fernandes J, Saudubray JM, van den Berghe G, Walter JH (eds) Inborn metabolic diseases diagnosis and treatment, 4th edn. Springer, Heidelberg, pp 294–306
Kölker S, Garbade SF, Greenberg CR et al (2006) Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 59:840–847
Kölker S, Garbade SF, Boy N, Maier EM, Meissner T, Mühlhausen C, Hennermann J, Brackmann R, Lücke T, Häberle J, Baumkötter J, Haller W, Christensen E, Koeller DM, Sauer SW, Zschocke J, Burgard P, Hoffmann GF (2007a) Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by neonatal screening in Germany. Pediatr Res 62:357–363
Kölker S, Christensen E, Leonard JV, Greenberg CR, Burlina AB, Burlina AP, Dixon M, Duran M, Goodman SI, Koeller DM, Muller E, Naughten ER, Neumaier-Probst E, Okun JG, Kyllerman M, Surtees RA, Wilcken B, Hoffmann GF, Burgard P (2007b) Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). J Inherit Metab Dis 30:5–22
Lindner M, Kölker S, Schulze A, Christensen E, Greenberg CR, Hoffmann GF (2004) Neonatal screening for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 27:851–859
Muhlhausen C, Christensen E, Schwartz N, Muschol K, Ullrich Z (2003) Severe phenotype despite high residual glutaryl-CoA dehydrogenase activity: a novel mutation in a Turkish patient with glutaric aciduria type I. J Inherit Metab Dis 26:713–714
Naughten ER, Mayne PD, Monavari AA, Goodman SI, Sulaiman G, Croke DT (2004) Glutaric aciduria type I, outcome in the Republic of Ireland. J Inherit Metab Dis 27:917–920
Nyhan WL, Zschocke J, Hoffmann G, Stein DE, Bao L, Goodman S (1999) Glutaryl-CoA dehydrogenase deficiency presenting as 3-hydroxyglutaric acidurias. Mol Genet Metab 66:199–204
Rashed MS (2001) Clinical applications of tandem mass spectrometry: 10 years of diagnosis and screening for inherited metabolic diseases. J Chromatogr B Biomed Sci Appl 758:27–48
Rinaldo P (2008) Organic acids. In: Blau N, Duran M, Gibson KM (eds) Laboratory guide to the methods in biochemical genetics. Springer, Berlin Heidelberg, pp 137–169
Sauer SW, Okun JG, Fricker G, Mahringer A, Müller I, Crnic LR, Mühlhausen C, Hoffmann GF, Hörster F, Goodman SI, Harding CO, Koeller DM, Kölker S (2006) Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood-brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. J Neurochem 97:899–910
Schor DSM, Verhoeven NM, Struys EA, ten Brink HJ, Jakobs C (2002) Quantification of 3-hydroxyglutaric acid in urine, plasma, cerebrospinal fluid and amniotic fluid by stable-isotope dilution negative chemical ionization gas chromatography-mass spectrometry. J Chromatogr B 780:199–204
Strauss KA, Puffenberger EG, Robinson DL, Morton DH (2003) Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet 121C:38–52
Tortorelli S, Hahn SH, Cowan TM, Brewster TG, Rinaldo P, Matern D (2005) The urinary excretion of glutarylcarnitine is an informative tool in the biochemical diagnosis of glutaric acidemia type I. Mol Gen Metab 84:137–143
Treacy EP, Lee-Chong A, Roche G, Lynch B, Ryan S, Goodman SI (2003) Profound neurological presentation resulting from homozygosity for a mild glutaryl-CoA dehydrogenase mutation with a minimal biochemical phenotype. J Inherit Metab Dis 26:72–74
Tsukamoto Y, Santa T, Saimaru H, Imai K, Funatsu T (2005) Synthesis of benzofurazan derivatization reagents for carboxylic acids and its application to analysis of fatty acids in rat plasma by high-performance liquid chromatography–electrospray ionization mass spectrometry. Biomed Chromatogr 19:802–808
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by: Verena Peters
Competing interest: None declared.
Rights and permissions
About this article
Cite this article
Al-Dirbashi, O.Y., Kölker, S., Ng, D. et al. Diagnosis of glutaric aciduria type 1 by measuring 3-hydroxyglutaric acid in dried urine spots by liquid chromatography tandem mass spectrometry. J Inherit Metab Dis 34, 173–180 (2011). https://doi.org/10.1007/s10545-010-9223-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-010-9223-2